Skip to content

NovoCure NVCR Book value per share

Book value per share at other companies

Boston Scientific logo
Boston ScientificBSX
$17.30+16.3%
Medtronic logo
MedtronicMDT
$38.40+3.1%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$1.72-27.5%
Nuvation Bio logo
Nuvation BioNUVB
$0.85-31.7%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$5.52-27.4%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$0.47-81.1%

Other financials

Income statement

See full
Revenue$174.1M+12.3%
Gross profit$135.1M+16.0%
Operating income-$67.4M-78.1%
Net income-$71.1M-107%
EPS (diluted)-$0.62-100%

Balance sheet

See full
Cash & equivalents$87.5M-31.2%
Total debt$39.5M-2.1%
Total equity$330.7M-8.6%
Total assets$787.9M-36.9%

Cash flow

See full
Operating cash flow-$13.5M+62.1%
CapEx$5.2M-51.4%
Free cash flow-$18.7M+59.7%

Valuation

See full
Market cap$1.64B-36.7%
Enterprise value$1.59B-36.3%
P/S2.4×-1.7×

Profitability

See full
Gross margin75.2%-2.0pp
Operating margin-27.2%+0.4pp
Net margin-25.7%-0.7pp
FCF margin-7.1%-2.0pp

Returns & leverage

See full
Return on equity-50%+5.4pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Where this comes from

Calculated from NovoCure’s reported figures.

Based on the most recent quarter.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NovoCure's book value per share?
NovoCure (NVCR) reported book value per share of $2.90 in Q1 2026.
How has NovoCure's book value per share changed year-over-year?
NovoCure's book value per share decreased by 11.7% year-over-year, from $3.28 to $2.90.
What is the long-term trend for NovoCure's book value per share?
Over 5 years (2020 to 2025), NovoCure's book value per share has grown at a -6.6% compound annual growth rate (CAGR), from $4.31 to $3.05.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.